Decisions of the Annual General Meeting of Biohit Oyj

Biohit Oyj Stock Exchange Release April 20, 2015 at 5:45 pm local time (EEST)
 

The Annual General Meeting (AGM) of Biohit Oyj held on Monday April 20, 2015 approved the financial statements of the parent company and the consolidated financial statements, and discharged the members of the Board of Directors and the President and CEO from liability for the financial year 2014.

Distribution of dividends

The AGM approved the Board of Directors proposal that no dividend shall be paid for the financial period ended on December 31, 2014.

Members of the Board of Directors

The AGM decided that the number of members of the Board of Directors would be six (6) an elected the following Board members until the end of the next AGM:  current members Professor Osmo Suovaniemi, Professor Mikko Salaspuro, Commercial Counselor Eero Lehti, M. Sc. Eng. Seppo Luode, Managing Director Franco Aiolfi and Master of Political Science Janina Andersson as a new member.

Additionally, the AGM decided that the Chairman of the Board of Directors would be paid a meeting fee of EUR 1,600 and the ordinary members of the Board would be paid a meeting fee of EUR 1,500.

Auditors

The AGM elected authorized public accountants PricewaterhouseCoopers Oy as the company’s auditor until the end of the next AGM. The auditor will be paid remuneration against the auditor’s invoice.

Amending the Articles of Association

In accordance with the proposal by the Board of Directors, the AGM decided that the Articles of Association be amended so that the paragraph 13 is removed. 

All decisions of the AGM were made unanimously. The minutes of the AGM will be available for review by shareholders by April 27, 2015 on the company’s website (www.biohithealthcare.com /investors) and at the corporate headquarters of Biohit, located at Laippatie 1, 00880 Helsinki.
 

Additional information:
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861
investor.relations@biohit.fi
www.biohithealthcare.com
 

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com